一文读懂 AD 诊断关键指标：脑脊液与血液检测浓度范围对比

参考文献：

[1] Teunissen CE, Verberk IMW, Thijssen EH, Vermunt L, Hansson O, Zetterberg H, van der Flier WM, Mielke MM, Del Campo M. Blood-based biomarkers for Alzheimer's disease: towards clinical implementation. Lancet Neurol. 2022 Jan;21(1):66-77. doi: 10.1016/S1474-4422(21)00361-6. Epub 2021 Nov 24. PMID: 34838239.

[2] Brickman AM, Manly JJ, Honig LS, Sanchez D, Reyes-Dumeyer D, Lantigua RA, Lao PJ, Stern Y, Vonsattel JP, Teich AF, Airey DC, Proctor NK, Dage JL, Mayeux R. Plasma p-tau181, p-tau217, and other blood-based Alzheimer's disease biomarkers in a multi-ethnic, community study. Alzheimers Dement. 2021 Aug;17(8):1353-1364. doi: 10.1002/alz.12301. Epub 2021 Feb 13. PMID: 33580742; PMCID: PMC8451860.

[3] Janelidze S, Stomrud E, Palmqvist S, Zetterberg H, van Westen D, Jeromin A, Song L, Hanlon D, Tan Hehir CA, Baker D, Blennow K, Hansson O. Plasma β-amyloid in Alzheimer's disease and vascular disease. Sci Rep. 2016 May 31;6:26801. doi: 10.1038/srep26801. PMID: 27241045; PMCID: PMC4886210.

[4] Lim YY, Maruff P, Kaneko N, Doecke J, Fowler C, Villemagne VL, Kato T, Rowe CC, Arahata Y, Iwamoto S, Ito K, Tanaka K, Yanagisawa K, Masters CL, Nakamura A. Plasma Amyloid-β Biomarker Associated with Cognitive Decline in Preclinical Alzheimer's Disease. J Alzheimers Dis. 2020;77(3):1057-1065. doi: 10.3233/JAD-200475. PMID: 32925048.

[5] Zhong X, Wang Q, Yang M, Lin G, Yao K, Wu Z, Xu D, Zhou H, Chen B, Shi H, Zhang M, Shi X, Zeng Y, Lao J, Liang S, Li J, Liu Q, Liu H, Chen Y, Lin Y, Ouyang C, Lv J, Liang X, Cheng Y, Ran P, Gong B, Zhang B, Guo J, Zhang H, Liu S, Zhang J, Liu H, Ning Y. Plasma p-tau217 and p-tau217/Aβ1-42 are effective biomarkers for identifying CSF- and PET imaging-diagnosed Alzheimer's disease: Insights for research and clinical practice. Alzheimers Dement. 2025 Feb;21(2):e14536. doi: 10.1002/alz.14536. Epub 2025 Jan 30. PMID: 39887504; PMCID: PMC11848202.

[6] Giacomucci G, Mazzeo S, Bagnoli S, Ingannato A, Leccese D, Berti V, Padiglioni S, Galdo G, Ferrari C, Sorbi S, Bessi V, Nacmias B. Plasma neurofilament light chain as a biomarker of Alzheimer's disease in Subjective Cognitive Decline and Mild Cognitive Impairment. J Neurol. 2022 Aug;269(8):4270-4280. doi: 10.1007/s00415-022-11055-5. Epub 2022 Mar 14. PMID: 35288777; PMCID: PMC9293849.

[7] Milà-Alomà M, Ashton NJ, Shekari M, Salvadó G, Ortiz-Romero P, Montoliu-Gaya L, Benedet AL, Karikari TK, Lantero-Rodriguez J, Vanmechelen E, Day TA, González-Escalante A, Sánchez-Benavides G, Minguillon C, Fauria K, Molinuevo JL, Dage JL, Zetterberg H, Gispert JD, Suárez-Calvet M, Blennow K. Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer's disease. Nat Med. 2022 Sep;28(9):1797-1801. doi: 10.1038/s41591-022-01925-w. Epub 2022 Aug 11. Erratum in: Nat Med. 2022 Sep;28(9):1965. doi: 10.1038/s41591-022-02037-1. PMID: 35953717; PMCID: PMC9499867.

[8] Wang X, Shi Z, Qiu Y, Sun D, Zhou H. Peripheral GFAP and NfL as early biomarkers for dementia: longitudinal insights from the UK Biobank. BMC Med. 2024 May 13;22(1):192. doi: 10.1186/s12916-024-03418-8. PMID: 38735950; PMCID: PMC11089788.

[9] Suárez-Calvet M. CSF p-tau231: A biomarker for early preclinical Alzheimer? EBioMedicine. 2022 Mar;77:103936. doi: 10.1016/j.ebiom.2022.103936. Epub 2022 Mar 12. PMID: 35290829; PMCID: PMC8919211.

探秘微观，引领生命科技前沿！精准偶联，开启分子操作新时代；超敏检测，赋能临床检验新应用！杭州乐为生医科技有限公司，精心打造多款科研利器：

选择乐为生医产品，解锁科研新可能。